OverviewSuggest Edit

Oncopeptides is a clinical development pharmaceutical company. It develops anti-cancer drugs. The Company has created Ygalo, a cytotoxic therapy that is in late-stage development use for the treatment of multiple myeloma.

TypePublic
Founded2000
HQStockholm, SE
Websiteoncopeptides.com

Latest Updates

Employees (est.) (Apr 2022)321
Revenue (FY, 2021)KR118.3 M
Share Price (May 2022)KR8.3(+5%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Oncopeptides

Brian Stuglik

Brian Stuglik

Director
Marty J Duvall

Marty J Duvall

Chief Executive Officer
Cecilia Daun Wennborg

Cecilia Daun Wennborg

Director
Paula Boultbee

Paula Boultbee

Chief Commercial Officer
Jarl Ulf Jungnelius

Jarl Ulf Jungnelius

Director
Eva Nordström

Eva Nordström

Vice President, Chief Operating Officer
Show more

Oncopeptides Office Locations

Oncopeptides has offices in Stockholm, Los Altos, Mountain View and Waltham
Stockholm, SE (HQ)
46 Luntmakargatan
Stockholm, SE
Tändstickspalatset, Västra Trädgårdsgatan 15
Los Altos, CA, US
4940 El Camino Real #100
Mountain View, CA, US
444 Castro St
Waltham, MA, US
200 5th Ave #1030
Show all (5)

Oncopeptides Financials and Metrics

Oncopeptides Revenue

Oncopeptides's revenue was reported to be kr118.3 m in FY, 2021
SEK

Revenue (FY, 2021)

118.3m

Gross profit (FY, 2021)

132.8m

Net income (FY, 2021)

(1.4b)

EBITDA (FY, 2021)

(1.4b)

EBIT (FY, 2021)

(1.4b)

Market capitalization (12-May-2022)

627.2m

Closing stock price (12-May-2022)

8.3

Cash (31-Dec-2021)

362.2m

EV

265.0m
Oncopeptides's current market capitalization is kr627.2 m.
Annual
SEKFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

118.3m

Cost of goods sold

(53.1m)

Gross profit

10.1m8.3m132.8m

R&D expense

(313.5m)(546.1m)(860.9m)(679.9m)
Quarterly
SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

19.4m66.4m54.3m

Cost of goods sold

(328.0k)(2.8m)(31.6m)

Gross profit

2.2m3.3m16.1m8.3m(8.3m)57.0m67.7m12.2m

R&D expense

(94.9m)(144.4m)(152.0m)(213.5m)(227.8m)(193.4m)(178.5m)(167.3m)(149.8m)
Annual
SEKFY, 2018FY, 2019FY, 2020FY, 2021

Cash

375.6m926.2m840.3m362.2m

Accounts Receivable

11.9m

Prepaid Expenses

14.7m44.0m32.3m12.2m

Inventories

8.7m
Quarterly
SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

747.5m626.8m1.1b617.8m937.8m1.3b372.5m999.4m671.3m

Accounts Receivable

21.4m72.8m72.9m

Prepaid Expenses

78.3m17.8m7.0m6.5m6.2m102.4m26.6m25.5m

Inventories

11.6m22.2m
Annual
SEKFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(411.0m)(739.4m)(1.6b)(1.4b)

Depreciation and Amortization

345.0k4.5m2.0m

Inventories

(429.0k)

Accounts Payable

9.6m55.7m55.1m
Quarterly
SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

(121.9m)(305.6m)(495.1m)(296.9m)(696.2m)(1.1b)(347.3m)(692.2m)(1.0b)
Show all financial metrics

Oncopeptides Revenue Breakdown

Embed Graph

Oncopeptides revenue breakdown by business segment: 100.0% from PHARMACEUTICAL DIVERSIFIED

Oncopeptides Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Oncopeptides Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Oncopeptides Online and Social Media Presence

Embed Graph

Oncopeptides News and Updates

Oncopeptides publishes the 2021 Annual Report

STOCKHOLM, April 21, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq: ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the 2021 Annual Report has been published. The Annual...

Oncopeptides publishes year-end report 2021

STOCKHOLM, Feb. 17, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the year-end report 2021. Financial overview October-December Net sales...

Oncopeptides publishes year-end report 2021

STOCKHOLM, Feb. 17, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the year-end report 2021. Financial overview October-December Net sales...

Oncopeptides phase 3 OCEAN study published in the Lancet Haematology

STOCKHOLM, Jan. 13, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the data from the randomized head-to-head phase 3 OCEAN study,...

Oncopeptides presents new melflufen data at the Annual American Society of Hematology Meeting ASH

STOCKHOLM, Dec. 10, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the company will present three posters on melflufen (INN...

Oncopeptides publishes Q3 2021 report

STOCKHOLM, Nov. 24, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the report for the third quarter 2021. Financial overview...
Show more

Oncopeptides Blogs

ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma

STOCKHOLM — December 21, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of a triple combination therapy with melflufen plus dexamethasone and subcutaneous daratumumab co…

Oncopeptides strengthens its organization by appointing Linda Holmström as Director of Investor Relations

STOCKHOLM — December 15, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases today announced that Linda Holmström has been appointed Director of Investor Relations. Linda has mo…

Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology

STOCKHOLM — December 9, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, today announces that the pivotal phase 2 HORIZON study evaluating intravenous melflufen (INN melpha…

Oncopeptides will host a webcast on Wednesday, December 9 at 14:00 (CET) to provide an update regarding data presented at the ASH annual meeting

STOCKHOLM — December 7, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases today announces that the company will host a webcast on Wednesday, December 9[th], 2020, at 14:00 (C…

INTERIM REPORT Q3 2020

Summary Financial overview July 1 – September 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 383.4 M (loss: 189.8) Loss per share, before and after dilution, was SEK 5.71 (loss: 3.53) On September 30 cash and cash equivalents amounted to SEK 1,251.6 M (1,122.3) Significan…
Show more

Oncopeptides Frequently Asked Questions

  • When was Oncopeptides founded?

    Oncopeptides was founded in 2000.

  • Who are Oncopeptides key executives?

    Oncopeptides's key executives are Brian Stuglik, Marty J Duvall and Cecilia Daun Wennborg.

  • How many employees does Oncopeptides have?

    Oncopeptides has 321 employees.

  • What is Oncopeptides revenue?

    Latest Oncopeptides annual revenue is kr118.3 m.

  • What is Oncopeptides revenue per employee?

    Latest Oncopeptides revenue per employee is kr368.5 k.

  • Who are Oncopeptides competitors?

    Competitors of Oncopeptides include Jiangsu Hansoh Pharmaceutical Group, 3sbio and Kyowa Kirin.

  • Where is Oncopeptides headquarters?

    Oncopeptides headquarters is located at 46 Luntmakargatan, Stockholm.

  • Where are Oncopeptides offices?

    Oncopeptides has offices in Stockholm, Los Altos, Mountain View and Waltham.

  • How many offices does Oncopeptides have?

    Oncopeptides has 5 offices.